Amgen: Lupus Erythematosus, Systemic trials

The registry lists 18 Lupus Erythematosus, Systemic studies with Amgen as lead sponsor. 1 are open to participants now and 6 have results posted.

Phase 1 12Phase 2 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesRecruitingNCT06570798Phase 2
• Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension StudyTerminatedNCT05430854Phase 2Results posted
• Study of VIB7734 for the Treatment of Moderate to Severely Active SLECompletedNCT04925934Phase 2Results posted
• Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus ErythematosusTerminatedNCT04680637Phase 2Results posted
• Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)CompletedNCT04058028Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus ErythematosusCompletedNCT03451422Phase 1Results posted
• Single Ascending Dose Study of AMG 570 in Healthy SubjectsCompletedNCT02618967Phase 1Results posted
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy ParticipantsCompletedNCT05984251Phase 1
• A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and DermatomyositisCompletedNCT03817424Phase 1
• A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus ErythematosusCompletedNCT02443506Phase 1
• A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus ErythematosusCompletedNCT02411136Phase 1
• A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus ErythematosusCompletedNCT02391259Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus ErythematosusCompletedNCT02291588Phase 1
• Safety Study of AMG 557 in Subjects With Lupus ArthritisCompletedNCT01683695Phase 1
• To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus ErythematosusCompletedNCT01300208Phase 2
• Safety Study of AMG 811 in Subjects With Discoid Lupus ErythematosusTerminatedNCT01164917Phase 1
• Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without GlomerulonephritisCompletedNCT00818948Phase 1
• A Study of AMG 557 in Adults With Systemic Lupus ErythematosusCompletedNCT00774943Phase 1